Patents by Inventor Sabine ROTTMANN

Sabine ROTTMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CCR7 ANTIBODY DRUG CONJUGATES
    Publication number: 20240092918
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: February 3, 2023
    Publication date: March 21, 2024
    Inventors: Steven BENDER, Tracy CHARLTON, Anna GALKIN, Bernhard Hubert GEIERSTANGER, Scott Martin GLASER, Shailaja KASIBHATLA, Mark KNUTH, Sabine ROTTMANN, Sarah RUE, Glen SPRAGGON, Tetsuo UNO
  • CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER
    Publication number: 20230181756
    Abstract: This application discloses compositions and methods of treating follicular lymphoma using CCR7 antibody drug conjugates. Also disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to said subject an antibody drug conjugate, wherein the cancer expresses CCR7, wherein the antibody drug conjugate is administered to said subject at about 0.1 mg/kg to about 10 mg/kg.
    Type: Application
    Filed: April 11, 2021
    Publication date: June 15, 2023
    Inventors: Vasileios ASKOXYLAKIS, Michelle COULSON, Anhthu DANG, Yuyan DUAN, Jessica MAKOFSKE, Sabine ROTTMANN, Xiaoli WANG
  • Anti-CCR7 antibody drug conjugates
    Patent number: 11634497
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: April 25, 2023
    Assignee: NOVARTIS AG
    Inventors: Steven Bender, Tracy Charlton, Anna Galkin, Bernhard Hubert Geierstanger, Scott Martin Glaser, Shailaja Kasibhatla, Mark Knuth, Sabine Rottmann, Sarah Rue, Glen Spraggon, Tetsuo Uno
  • ANTI-CCR7 ANTIBODY DRUG CONJUGATES
    Publication number: 20200216548
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: February 1, 2018
    Publication date: July 9, 2020
    Inventors: Steven BENDER, Tracy CHARLTON, Anna GALKIN, Bernhard Hubert GEIERSTANGER, Scott Martin GLASER, Shailaja KASIBHATLA, Mark KNUTH, Sabine ROTTMANN, Sarah RUE, Glen SPRAGGON, Tetsuo UNO